Sergei Grivennikov, PhD
- PhD, Engelhardt Institute of Molecular Biology, 2004
- MS, Moscow State University, 2000
Honors & Awards
- Landon Innovator Award in Tumor Microenvironment, AACR 2014
- Pew Scholar, Biomedical Sciences 2013
- Pathway to Independence Award , NIH, K99/R00 2011
- Career Development Award, Crohn’s & Colitis Foundation of America 2011
- Award for Postdoctoral Fellows, National Institutes of Health 2005
- Research Fellowship Award, Crohn’s & Colitis Foundation of America 2007
How immune and inflammatory pathway promote tumor growth and progression
- Role of cytokines in tumor development
- Mechanisms of tumor-elicited inflammation
- Role of inflammatory pathways in normal regeneration and in response to anti-cancer therapies
- Mouse models of inflammation and cancer
It has become recently clear that Inflammation plays important roles at different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis. Immune cells that infiltrate tumors engage in an extensive and dynamic crosstalk with cancer cells and some of the molecular events that mediate this dialog have been revealed. Inflammatory microenvironment is an essential component of all tumors, including some in which a direct causal relationship with inflammation is not yet proven. Importantly, only a minority of all cancers are caused by germline mutations, whereas the vast majority (90%) are linked to somatic mutations or epigenetic changes and environmental factors, including preceding chronic inflammation. Recent studies provided further evidence about the connection between inflammation and cancer, as non-steroid anti-inflammatory drugs such as aspirin, significantly lower the risk of cancer death. Several types of tumor-associated inflammation have been outlined, which either pro- or anti-tumorigenic effect. Given the importance of the functional interaction between immune cells and cancer cells, the outstanding question is what mediates such a cross-talk?
Our research interests are to connect various immune signaling pathways with pathogenesis of inflammation-associated and sporadic cancers, including colon cancer.
Research in the lab utilizes various genetic animal models of immunodeficiency and cancer as well as human tissues, and follows several major directions:
1. Examine the role of various inflammatory cytokine pathways in regulation of tumor-elicited inflammation tumor growth, invasion and metastasis.
2. Explore the mechanisms of how inflammatory response in the tumors is induced, including potential contribution of microbiota and endogenous factors produced by the host.
3. How manipulations with the strength and specificity of the host inflammatory response may aid in the development of better preventive and therapeutic strategies.
Oxana Dmitrieva, MD
Former staff members:
David Posocco, BS, Scientific Technician
Debora Vendramini, PhD, Visiting Postdoctoral Researcher
Ralph Francescone, PhD, Postdoctoral Researcher
Koltsova EK, Grivennikov SI. IMPlicating Mesenchymal Imp1 in Colitis-Associated Cancer. Mol Cancer Res. 2015 Nov;13(11):1452-4. doi: 10.1158/1541-7786.MCR-15-0385. Epub 2015 Oct 9. PubMed
Francescone R, Hou V, Grivennikov SI. Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis. 2015 Feb;21(2):409-18. doi: 10.1097/MIB.0000000000000236. Review. PubMed
Wang K, Kim MK, Di Caro G, Wong J, Shalapour S, Wan J, Zhang W, Zhong Z, Sanchez-Lopez E, Wu LW, Taniguchi K, Feng Y, Fearon E, Grivennikov SI, Karin M. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity. 2014 Dec 18;41(6):1052-63. doi: 10.1016/j.immuni.2014.11.009. Epub 2014 Nov 25. PubMed
Francescone R, Hou V, Grivennikov SI. Microbiome, inflammation, and cancer. Cancer J. 2014 May-Jun;20(3):181-9. PubMed
Koltsova EK, Grivennikov SI. IL-22 gets to the stem of colorectal cancer. Immunity. 2014 May 15;40(5):639-41. doi: 10.1016/j.immuni.2014.04.014. PubMed
Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012 Nov 8;491(7423):254-8. PubMed
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010 Mar 19;140(6):883-99. PubMed